Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QLF31907 in advanced melanoma and urothelial carcinoma
ChiCTR2300070699Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QLF31907 in melanoma and transitional cell carcinoma (TCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Dose-limiting toxicity, Adverse events and 2 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
QLF31907
03
Conditions
melanomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2300070699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070699.